Featured Speakers

• 

  Laszlo UrbanGlobal Head, Preclinical Safety Profiling Novartis

• 

  Federico GoodsaidVP, Strategic Regulatory Intelligence Vertex Pharmaceuticals

• 

  Eric ChiaoHead, Pluripotent Stem Cell Lab, Non-Clincal Safety Roche

• 

  Linda GriffithProfessor MIT

• 

  Peter HoffmannExecutive Director, Preclinical Safety Novartis

• 

  Mike ShulerProfessor Cornell University

• 

  Yvonne WillSenior Principal Scientist Pfizer

• 

  Gary GintantSenior Group Leader Abbott

Arm yourself with the information you need to direct your in vitro modeling strategy towards enhanced clinical success

With low efficacy and high toxicity accounting for 70% of Phase II and 87% of Phase III clinical attrition, improving predictive in vitro models has never been such a high priority.

The 3rd Annual Developing More Predictive In Vitro Models Summit will showcase a range of new platforms and technologies that address this issue directly. High potential compounds will be prioritized, toxicity mitigated and clinical strategy directed by development and validation of this new breed of in vitro models.

During research for this meeting, your peers asked for an agenda packed full with the latest improvements in established in vitro models and exciting developments in 3D culture, stem cell and lab-on-a-chip technologies. With candid discussion on these issues guaranteed from senior level figures at the FDA, Novartis, Roche, Abbott, Pfizer and many more, this meeting will provide the most valuable strategic learning experience of the year.

Don’t miss out on this chance to go back to the lab with the tools to direct your preclinical and clinical strategy towards improved clinical performance.

Benefits of attending:

• Learn how to avoid costly clincial attrition and maximize your ROI by using in vitro modeling to inform swift and accurate decision making at critical junctures in drug development
• Find out how harnessing in silico and 3D culture technology will allow you to develop more predictive preclinical models
  
• Get the latest updates on developing a panel of assays to assess hepatotoxicity and highlight potential clinical toxicity
  
• Discover the potential of applying stem cell models to early stage clinical development
• Get expert insight into the regulatory requirements to achieve scientific validation of new in vitro models

Who should attend this meeting:

• Drug developers motovated by increasing clinical success and reducing drug development costs
• Clinicians with a keen interest in mitigating the toxicity and improving the efficacy of candidate compound
• Scientists and academics working in tissue engineering, toxicology and systems biology
• Biotechs and solution providers developing exciting and innovative in vitro models

What next?

• View the agenda online or download the brochure to see exactly what will be covered
• Don't forget to check out the interactive pre-conference workshops
• Choose your package - see the prices and discounts available here
• Book your place! You can register online, by phone or by email

If you have any questions about the meeting or registration process then please don;t hesitate to get in touch.